Reata Pharmaceuticals — Q3 2021 Earnings Presentation
17 slides from Reata Pharmaceuticals's earnings presentation, Nov 8, 2021
Slide 1: 3rd Quarter 2021 Financial Results and Update on Clinical Development Programs
November 8, 2021 3rd Quarter 2021 Financial Results and Update on Clinical Development Programs Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg
Slide 3: Today's Agenda
Today’s Agenda
Slide 4: Bardoxolone in CKD
Bardoxolone in CKD
Slide 5: Regulatory Update on Bardoxolone for Patients with CKD Caused by Alport Syndrome
Regulatory Update on Bardoxolone for Patients with CKD Caused by Alport Syndrome CKD: Chronic Kidney Disease; PDUFA: Prescription Drug User Fee Act; MAA: Marketing Authorization Application; PMDA: Pharmaceuticals and Medical Devices Agency
Slide 6: Advisory Committee Preparations
Advisory Committee Preparations FDA: U.S. Food and Drug Administration; KOL: Key Opinion Leader Submitted Advisory Committee meeting briefing book to FDA Working with external KOLs who will join us in our Advisory Committee meeting bullpen Completed mock Advisory Committee meetings with former panel
Slide 7: FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD
FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD ADPKD: Autosomal Dominant Polycystic Kidney Disease; eGFR: estimated Glomerular Filtration Rate International, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial of bardoxolone in patients with ADPKD Primary endpoint: o
Slide 8: Omaveloxolone in Friedreich's Ataxia
Omaveloxolone in Friedreich’s Ataxia
Slide 9: Regulatory Update on Omaveloxolone for Patients with Friedreich's Ataxia
Regulatory Update on Omaveloxolone for Patients with Friedreich’s Ataxia NDA: New Drug Application; 1Per FDA’s discretion, subject to review
Slide 10: Commercial Readiness Preparation
Commercial Readiness Preparation
Slide 11: Commercial Launch Preparation
Commercial Launch Preparation Alport Syndrome: Completed Friedreich’s Ataxia: Re-Initiated
Slide 12: ov ~ o ns] a =) ie) c o c a HBREATA.
ov ~ o ns] a =) 2 ie) c o c a HBREATA.
Slide 13: Q3 2021 Cash & Shares; Financial Guidance and Summary
Q3 2021 Cash & Shares Cash $713.2M Total Shares Outstanding 36.4M 31.5M class A shares outstanding 4.9M class B shares outstanding 2021 Financial Guidance Based on our operational plans, we anticipate cash runway through mid-2024 Financial Summary 1Excludes stock-based compensation expenses; 2GAAP a
Slide 14: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures
Slide 15: Concluding Remarks
Concluding Remarks
Slide 16: Reata at a Glance
Reata at a Glance NDA for bardoxolone in CKD caused by Alport syndrome under review AdCom meeting Dec 8, 2021; PDUFA date Feb 25, 2022 FALCON enrolled >450 patients; protocol to be amended Pre-NDA meeting for omaveloxolone in FA completed Plan to submit NDA during Q1 2022 Updated plan to initiate Ph
Slide 17: Thank you
Thank you
Reata Pharmaceuticals — Q3 2021 Earnings Presentation on 6ix